Investigational Drug Information for AGN-2979
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug AGN-2979?
AGN-2979 is an investigational drug.
There have been 59 clinical trials for AGN-2979.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2022.
The most common disease conditions in clinical trials are Presbyopia, Ocular Hypertension, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and AbbVie.
There are eight US patents protecting this investigational drug and seventy-seven international patents.
Summary for AGN-2979
| US Patents | 8 |
| International Patents | 77 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2022-12-01) |
| Vendors | 6 |
Recent Clinical Trials for AGN-2979
| Title | Sponsor | Phase |
|---|---|---|
| Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses | AbbVie | Phase 4 |
| Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses | Gordon Schanzlin New Vision | Phase 4 |
| AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients | Milton S. Hershey Medical Center | Phase 1 |
Clinical Trial Summary for AGN-2979
Top disease conditions for AGN-2979
Top clinical trial sponsors for AGN-2979
US Patents for AGN-2979
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AGN-2979 | ⤷ Try a Trial | Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines | G. D. Searle & Co. (Chicago, IL) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Memory-enhancing compositions containing dioxopiperidine derivatives | National Research Development Corporation (London, GB2) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Process for the preparation of diethyl 2-]2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1,1-dimethylpentyl]prop andioate | G. D. Searle & Co. (Chicago, IL) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Piperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders | Prestwick Pharmaceuticals, Inc. (Washington, DC) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders | Prestwick Pharmaceuticals, Inc. (Washington, DC) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Method for treating intestinal fibrosis | Sigmoid Pharma Limited (Dublin, IE) | ⤷ Try a Trial |
| AGN-2979 | ⤷ Try a Trial | Immunomodulatory compositions | Sigmoid Pharma Limited (Dublin, IE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AGN-2979
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AGN-2979 | Canada | CA2036968 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | European Patent Office | EP0448972 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | Ireland | IE910656 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | Japan | JPH04211657 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | Japan | JPH0694460 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | Portugal | PT96883 | 2010-02-27 | ⤷ Try a Trial |
| AGN-2979 | Austria | AT79754 | 2008-11-10 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
